A Multi-center Phase I/Ib Study Evaluating the Efficacy and Safety of Brentuximab Vedotin in Combination With TGR-1202, a Novel PI3K Delta Inhibitor, in Patients With Hodgkins Lymphoma
Phase of Trial: Phase I
Latest Information Update: 09 Sep 2019
Price : $35 *
At a glance
- Drugs Umbralisib (Primary) ; Brentuximab vedotin
- Indications Hodgkin's disease
- Focus Adverse reactions
- Sponsors TG Therapeutics Inc
- 03 Sep 2019 Status changed from active, no longer recruiting to completed.
- 14 May 2019 Planned End Date changed from 1 Feb 2019 to 1 Sep 2019.
- 12 Sep 2018 Planned End Date changed from 1 Aug 2018 to 1 Feb 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History